Yuhan Corp. (000100.KS) stock: key figures, P/E, revenue and dividend

Health Care · Pharmaceuticals · South Korea · ISIN KR7000100008

Price
75,200.00 KRW
Market cap
5.54 tn KRW
P/E (2025)
28.52
P/S (2025)
2.53
Dividend yield
0.80 %
Net margin
8.88 %
Return on equity (ROE)
8.41 %
Return on assets (ROA)
6.03 %

Yuhan Corp. financials

Fiscal year20242025
Revenue2.07 tn KRW2.19 tn KRW
Gross profit689.39 bn KRW729.92 bn KRW
Operating income54.88 bn KRW104.37 bn KRW
EBIT76.16 bn KRW238.08 bn KRW
Net income70.69 bn KRW194.08 bn KRW
Diluted EPS – continuing operations957.90 KRW2,636.38 KRW

Full history since 2000, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

Sign up for freeOpen interactive view

About Yuhan Corp.

Yuhan Corporation operates as a pharmaceutical company in South Korea and internationally. It offers manufacturing services, such as custom manufacturing; process research and development of active pharmaceutical products (APIs) and intermediates; kilo and pilot-scale production of APIs and intermediates; commercial production of APIs and intermediates; production of chemical specialties; and analytical method development and regulatory support. The company also provides APIs and intermediates, including antibiotic, anti-thrombotic, anti-hyperlipidemics, and anti-hypertensive; and custom synthesis services through commercial supply in areas of anti-viral, anti-HIV, anti-HCV, anti-biotic, antihistamine, anti-diabetic, ß-lactamase inhibitor, CNS intermediate, PEG-compounds, and others. Yuhan Corporation was founded in 1926 and is headquartered in Seoul, South Korea.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.